Participated · Series A · Aug 2025

Reframe Systems develops regional, deployable microfactories that use proprietary software, vision-guided robots, and physical AI to automate framing, sheathing, and insulation and enable mass-customized, site-specific homes. Its microfactories can be launched in 100 days and manufacture up to five single-family homes per week, delivering homes 2.5× faster while reducing costs by 35%. Homes produced are designed to meet local codes and resilience standards — all-electric, solar-ready, and built with fire-resilient materials and features. The company was founded by former Amazon Robotics leaders Vikas Enti, Felipe Polido, and Aaron Small and is accelerating projects in the Boston area (Somerville, Devens, Woburn) and pilot work in Altadena, CA, with plans for a Southern California microfactory. Reframe aims to scale its model widely with a stated mission to build one million homes by 2045. The Series A capital will support scaling its microfactory network and deployment to address the U.S. housing shortage and construction labor shortfall.

Participated · Series A · Jun 2024

Tender Food develops structured plant-based meat alternatives (beef short rib, pulled pork, chicken breast and crab) using a fiber-spinning process that spins soy proteins into textured cuts. Founded in 2020 and formerly known as Boston Meats, the company has shifted from R&D toward commercialization. Its products are already in restaurants, universities and 11 Clover Food Lab locations in the Boston area, and it is trialing with foodservice companies and large food manufacturers. Tender plans to scale co-manufacturing to millions of pounds of product and to continue product development. The company recently added Mike Messersmith, former North American president of Oatly, to its board to support the transition to commercial operations. Revenue was previously not a major focus but will be prioritized as the company commercializes. Tender Food develops alternative meats with authentic texture, specializing in whole-muscle cut products such as chicken breasts, pulled pork and steaks. Its technology, derived from materials and protein fiber manufacturing work in Kevin Kit Parker’s Harvard lab, enables products that look, taste and feel like real meat. The approach supports both plant-based and cultured meat applications. Launched in 2020 by Harvard engineers, the company is led by CEO Christophe Chantre, a former postdoctoral research fellow at the Wyss Institute. Based in the Greater Boston Area, Tender sits in a hub for biotech research and innovation. The company raised $12M in Seed funding to scale up production and plans to launch its first products later this year.

Participated · Series A · Feb 2024

Anthro Energy develops lithium-ion batteries and a scalable polymer-electrolyte technology designed to resolve the tradeoff between energy density and safety, enabling safer, more stable battery form factors. The company has deployed prototype cells to customers in sectors from consumer electronics to electric vehicles and has demonstrated market traction and technical validation. Anthro recently completed UN 38.3 certification for cells containing its proprietary polymer electrolyte, a third-party test that certifies safe transportation and advances commercialization. The company intends to use its new funding to build a Bay Area pilot production facility to commercialize and scale its technologies. Anthro was spun out of Stanford University, is led by CEO David Mackanic, and is supported by a range of government grants. Anthro Energy builds lithium-ion cells around a rubber-like, flexible polymer electrolyte that lets batteries bend without shorting. The core product is a highly ion-conductive, tough electrolyte that keeps electrodes separated during deformation and is less prone to catching fire than liquid electrolytes. The material originated in co-founder David Mackanic’s doctoral research at Stanford, and the company engineered it for manufacturability with existing battery equipment via minor formation-process tweaks. Anthro is initially targeting wearable electronics and medical-device makers, with early demos swapping rubber watch straps for batteries and partners lined up for validation. The startup is constructing a prototype production line to produce roughly 50–100 batteries per day and will use its seed funding to expand the team and scale prototyping. Management expects partner qualification within about a year and consumer-available devices six to 12 months after that, while viewing automotive applications as a potential larger-market opportunity down the line.

Participated · Series A · Nov 2023

Aclarity develops Octa™ PFAS destruction systems that use proprietary electricity-driven technology to sever carbon–fluorine bonds and destroy persistent PFAS "forever chemicals." The company is led by founder and CEO Julie Bliss Mullen and is based in Mansfield, MA. It closed a $15.9m Series A funding round to support commercial expansion and continued innovation. The Series A was led by Aqualateral, with participation from HG Ventures, Bidra Innovation Ventures, Nor’easter Ventures, MassVentures, and Burnt Island Ventures. Aclarity positions its technology as an alternative to conventional PFAS removal and disposal methods—such as landfill disposal, incineration, and deep well injection—that can reintroduce concentrated PFAS into the environment. The company intends to use the proceeds to enter a new phase of commercial expansion and product development. Aclarity develops a proprietary electrochemical reactor that destroys PFAS and other contaminants by generating strong oxidants (free electrons, hydroxyl radicals, ozone and chlorine) inside a flow-through reactor, producing inert byproducts rather than transferring contaminants to filter media. The system treats multiple contaminants including PFAS, ammonia, cyanide, volatile organic compounds and pathogens and is sold as an alternative to capture-and-incinerate, deep-well injection or landfill disposal. Aclarity targets owners of centralized waste treatment facilities that process concentrated industrial wastewater and landfill leachate and completed its first commercial multi-reactor install in late 2021, processing 11 gallons per minute to destroy cyanide with an initial six-month payback. The company says its system costs roughly $6 per 1,000 gallons with an indicated payback around two years, versus customers currently paying about $60 per 1,000 gallons under existing approaches. Aclarity plans to double its team to 13 employees this year, complete two long-term pilots at customer sites and develop a model for a 2023 pilot, aiming to scale deployment of its technology amid a large market opportunity. Aclarity is a Springfield, MA–based cleantech company addressing global water crises with water purification devices. Its core patent-pending product, launched in Spring 2019, uses electricity to destroy harmful pathogens, metals, bacteria and other impurities for homes, offices and industrial facilities. The company began commercial sales in mid-2019 and is currently taking orders. Aclarity raised over $1m in pre-seed funding to accelerate its go-to-market strategy. It plans to use the capital to expand into new product lines and scale operational capacity. Since 2017 the company has participated in early technology commercialization training programs from local and national accelerators and received a National Science Foundation SBIR Phase I Grant.

Participated · Seed · Mar 2022

ArrePath combines proprietary AI/ML with experimental chemistry to accelerate antibacterial drug discovery. Its platform couples virtual and experimental compound design and testing to identify novel compounds with the attributes required to progress. The company has identified antibiotic hits active against three clinically novel targets and is advancing lead program AP-001 toward development candidate nomination and eventual Phase 1 studies. Recent non-dilutive funding awards from PACE and CARB-X, together with its latest financing, support these development efforts. The new financing will also back expansion of novel compounds active against non-tuberculous mycobacteria (NTM) and programs targeting the outpatient UTI market and hospital-avoidance strategies. ArrePath is headquartered in Princeton, N.J. ArrePath applies a proprietary AI/ML platform and deep phenotypic imaging to discover new classes of anti-infective small molecules with mechanisms distinct from current antibiotics. Its lead program is designed to be active against multidrug-resistant Gram-negative pathogens, including E. coli and Klebsiella pneumoniae. The company plans to advance the lead candidate through IND-enabling studies with a potential first clinical indication of complicated urinary tract infections caused by MDR organisms. Development includes a dual delivery approach—both intravenous and oral—to support use across healthcare settings. ArrePath was awarded a £1 million non-dilutive grant from PACE to support these activities. The company is based in Princeton, N.J. ArrePath develops a proprietary ML-based platform that decodes complex bacterial behavior (so-called 'bacterial autopsies') to identify and optimize anti-infective agents with novel mechanisms of action. The platform couples imaging and machine learning to enable rapid identification and differentiation of compounds early in discovery. Proof-of-concept work from the company’s scientific founder, Zemer Gitai, was published in Cell in June 2020 and has identified compounds with novel dual mechanisms. ArrePath is a Princeton University spin-out and holds an exclusive option to license related intellectual property and novel compounds generated by the platform. The company recently appointed Dr. Lloyd Payne as President and CEO; he brings more than 25 years of scientific and business leadership in anti-infective discovery, including leadership roles at Evotec and founding Euprotec. The new funding is intended to advance initial leads, expand discovery efforts, and enhance the company’s imaging platform and application of machine learning.